Benefits of Genetic Technologies, Agricultural, Medical and Industrial Uses

Evaluative frame · "beneficial for whom, vs what?"

He Jiankui's 2018 CRISPR edit of human embryos aimed at a genuine medical benefit: CCR5 deletion is associated with HIV resistance, and the children were born to an HIV-positive father. Yet the global scientific community condemned the work. By contrast, recombinant insulin (Humulin, FDA-approved 1982) is widely accepted as beneficial. The difference is not technology type, both used genetic modification. The difference is consent, germline heritability, risk-benefit proportionality, and whether the individuals most affected had agency in the decision.

In HSC responses, the strongest evaluation asks what kind of benefit is being discussed. Higher crop output is an agricultural benefit. Greater access to useful medicines is a medical benefit. Lower-cost or more efficient biological manufacturing is an industrial benefit. Those are not the same claim, so they should not be collapsed into one vague statement.

Evaluating a genetic technology as "beneficial" requires specifying domain (agricultural/medical/industrial), for whom, and compared with what alternative, generic claims such as "it helps people" are insufficient for HSC evaluation.

Pause, copy the highlighted evaluative requirement into your book before moving on.

Application domain · the most trade-off-heavy

We just saw that claims about benefit must be tied to a specific domain and comparison. That raises a question: what does evaluation look like for agricultural biotechnology specifically? This card answers it → agricultural benefits and biodiversity trade-offs.

These are real benefits because they can improve food production, reduce losses and sometimes improve food quality. But a strong answer must not stop at productivity. Agriculture is the domain where biodiversity trade-offs become especially important.

Agricultural benefits include improved yield, resistance traits and nutritional modification, but agricultural biotechnology also carries the strongest biodiversity trade-offs, reliance on a narrow range of successful genotypes can reduce genetic diversity and lower resilience.

Add the highlighted point to your notes before the check below.

Application domain · controlled biological production

We just saw that agricultural benefits come with biodiversity trade-offs. That raises a question: how are medical benefits both similar and different? This card answers it → medical biotechnology and controlled biological production.

The key medical idea is usefulness through controlled production and targeted biological effect. This is why gene cloning and recombinant DNA technology matter beyond the laboratory: they support actual medical application.

Medical benefits centre on controlled biological production of useful proteins (e.g. insulin) and targeted treatment support, the key idea is usefulness through controlled production, which is why gene cloning and recombinant DNA matter beyond the laboratory.

Pause, write the highlighted principle into your book.

Application domain · same logic as medicine

We just saw that medical benefits come from controlled biological production of useful proteins. That raises a question: how does industrial biotechnology follow the same logic? This card answers it → industrial enzymes and biological manufacturing.

Industrial application is often the least intuitive for students, but it follows the same logic as medicine: once a biological system can be directed to make a useful product, it can become part of a manufacturing process.

Industrial benefits include enzyme production and biological manufacturing at scale, this follows the same logic as medicine: once a biological system can be directed to make a useful product, it becomes part of a manufacturing process, not just a research tool.

Pause, copy the highlighted comparison into your notes before continuing.

Agricultural evaluation · the high-yield judgement

We just saw that industrial biotechnology shares production logic with medical biotechnology. That raises a question: how should the biodiversity trade-off in agriculture be addressed in a final evaluation? This card answers it → balancing agricultural benefit against biodiversity risk.

Agricultural biotechnology may improve yield, resistance or nutrition, but it can also reduce diversity if systems become dominated by a narrow range of genotypes. This matters because biodiversity is linked to resilience, not just immediate output.

Agricultural benefit does not cancel biodiversity trade-offs, reliance on a few successful genotypes reduces diversity, and lower diversity reduces resilience; the strongest HSC judgement states the benefit, names the biodiversity risk, and ends with conditional, balanced language.

Pause, write the highlighted evaluative principle into your book.